New avenues for NASH therapy by targeting ACC.
Sign Up to like & getrecommendations! Published in 2022 at "Cell metabolism"
DOI: 10.1016/j.cmet.2022.01.001
Abstract: Acetyl-CoA carboxylase (ACC) is one of the more promising therapeutic targets for non-alcoholic steatohepatitis (NASH), but current ACC inhibitors already tested in clinical trials also exert the unwanted adverse side effect of hypertriglyceridemia. In two… read more here.
Keywords: medicine; avenues nash; nash therapy; new avenues ... See more keywords